Changeflow GovPing Pharma & Drug Safety Cysteamine for Treatment, Mitigation and Preven...
Routine Rule Added Final

Cysteamine for Treatment, Mitigation and Prevention of SARS-CoV-2 Infections

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

USPTO published patent application US20260097007A1 for cysteamine and derivatives for treating COVID-19 and related viral infections. Inventors are Jess Thoene and Robert Gavin. The application (No. 19415604) was filed December 10, 2025, and published April 9, 2026.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO published patent application US20260097007A1 covering methods for treating, mitigating, and preventing coronavirus infections (including SARS-CoV-2 and COVID-19) using cysteamine or derivatives thereof. The application includes therapeutic method claims and pharmaceutical composition claims across multiple CPC classifications.

Pharmaceutical companies and researchers developing antiviral therapeutics should monitor this application as it may affect freedom-to-operate considerations for cysteamine-based treatments. Patent applicants and investors in COVID-19 therapeutics may find this application relevant for competitive intelligence purposes.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 11, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

CYSTEAMINE FOR THE TREATMENT, MITIGATION AND PREVENTION OF CORONAVIRAL, E.G., SARS-CoV-2, INFECTIONS

Application US20260097007A1 Kind: A1 Apr 09, 2026

Inventors

Jess Thoene, Robert Gavin

Abstract

Provided herein are methods for the treatment, mitigation, and prevention of viral infections (e.g., coronavirus infections (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.), etc.) and diseases (e.g., Coronavirus disease 2019 (COVID-19)) associated therewith by the administration of cysteamine or derivatives thereof to a subject.

CPC Classifications

A61K 31/145 A61K 9/0043 A61K 9/0053 A61K 31/4045 A61K 31/427 A61K 31/4706 A61K 31/4965 A61K 31/513 A61K 31/661 A61K 31/675 A61P 31/14

Filing Date

2025-12-10

Application No.

19415604

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260097007A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Pharmaceutical R&D
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!